Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERCC1 | P07992 | 1/20 | 0.45 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.45 |
| ▸ | FEN1 | P39748 | 1/20 | 0.45 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.45 |
| ▸ | PDE1A | P54750 | 8/20 | 0.43 |
| ▸ | PDE1B | Q01064 | 8/20 | 0.43 |
| ▸ | PDE1C | Q14123 | 8/20 | 0.43 |
| ▸ | PDE2A | O00408 | 6/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | CFTR | P13569 | 2/20 | 0.43 |
| ▸ | PDE5A | O76074 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | PDE4A | P27815 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.43 |
| ▸ | SCN1A | P35498 | 1/20 | 0.43 |
| ▸ | PDE6C | P51160 | 1/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.43 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7856501 | 0.87 | PDE1A (0.37) | ERCC1ERCC5FEN1ERCC4PDE1A | |
| SCHEMBL6514929 | 0.77 | ADORA2B (0.40) | ERCC1ERCC5FEN1ERCC4CYP1A2 | |
| SCHEMBL7008006 | 0.77 | PARG (0.43) | ERCC1ERCC5FEN1ERCC4PDE5A | |
| SCHEMBL6636939 | 0.76 | HTR4 (0.39) | ERCC1ERCC5FEN1ERCC4CYP1A2 | |
| SCHEMBL19759435 | 0.75 | PDE1A (0.46) | PDE1APDE1BPDE1CPDE2ATSHR | |
| SCHEMBL6345596 | 0.74 | PDE1A (0.43) | PDE1APDE1BPDE1CPDE2ATSHR | |
| SCHEMBL7010765 | 0.73 | SLC16A1 (0.38) | PDE1APDE1BPDE1CPDE2ATSHR | |
| SCHEMBL6516737 | 0.73 | ADORA2B (0.44) | ERCC1ERCC5FEN1ERCC4PDE4A | |
| SCHEMBL2207892 | 0.73 | HSD17B10 (0.39) | ERCC1ERCC5FEN1ERCC4PDE1B | |
| SCHEMBL6670689 | 0.73 | ALDH1A1 (0.40) | ERCC1ERCC5FEN1ERCC4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3247360-A1 | HETEROCYCLIC INHIBITORS OF MONOCARBOXYLATE TRANSPORTERS | The Scripps Research Institute (US) | 2017-11-29 | — | — | EP | disclosed |
| WO-2016118825-A1 | HETEROCYCLIC INHIBITORS OF MONOCARBOXYLATE TRANSPORTERS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2016-07-28 | — | — | WO | disclosed |
| US-6984644-B2 | Treatment of skin disorders using thieno[2,3-D]pyrimidinediones | ASTRAZENECA AB (SE) | 2006-01-10 | — | — | US | disclosed |
| US-6890923-B2 | Compounds | ASTRAZENECA AB (SE) | 2005-05-10 | — | — | US | disclosed |
| EP-1280806-B1 | THIENO 2,3-d]PYRIMIDINEDIONES AND THEIR USE AS PHARMACEUTICALS | ASTRAZENECA AB (SE) | 2004-08-04 | — | — | EP | disclosed |
| US-20040122028-A1 | Novel compounds | ASTRAZENECA AB (SE) | 2004-06-24 | — | — | US | disclosed |
| US-20040014634-A1 | Thieno[2,3-d]pyrimidinediones and their use as pharmaceuticals | ASTRAZENECA AB (SE) | 2004-01-22 | — | — | US | disclosed |
| EP-1107973-B1 | NOVEL THIENO[2,3-d]PYRIMIDINEDIONES, PROCESS FOR THEIR PREPARATION AND USE THEREOF IN THERAPY | ASTRAZENECA AB (SE) | 2003-11-05 | — | — | EP | disclosed |
| US-20030191142-A1 | Thieno[2,3-d]pyrimidinediones, their preparation and use in therapy | ASTRAZENECA AB | 2003-10-09 | — | — | US | disclosed |
| US-20020183337-A1 | For use in immunosuppression; for reducing the risk of, a reversible obstructive airways disease | ASTRAZENECA AB. | 2002-12-05 | — | — | US | disclosed |
| US-6469014-B1 | IMMUNOSUPPRESSIVE ACTIVITY | ASTRAZENECA AB (SE) | 2002-10-22 | — | — | US | disclosed |
| EP-0991653-B1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2002-10-16 | — | — | EP | disclosed |
| US-6342502-B1 | ANTIASTHMATICS | ASTRAZENECA AB (GB) | 2002-01-29 | — | — | US | disclosed |
| US-6300334-B1 | DRUGS FOR TREATMENT OF RESPIRATORY SYSTEM DISORDERS | ASTRAZENECA AB (SE) | 2001-10-09 | — | — | US | disclosed |
| EP-1107973-A1 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2001-06-20 | — | — | EP | disclosed |
| US-6180635-B1 | NOVEL THIENO(2,3-D)PYRIMIDINEDIONES WHICH EXHIBIT PHARMACOLOGICAL ACTIVITY, IN PARTICULAR IMMUNOSUPPRESSIVE ACTIVITY; TREATING ALLOGRAFT REJECTION | ASTRAZENECA UK LIMITED (GB) | 2001-01-30 | — | — | US | disclosed |
| EP-0991653-A1 | NOVEL COMPOUNDS | Astra Pharmaceuticals Limited (GB) | 2000-04-12 | — | — | EP | disclosed |
| WO-2000012514-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2000-03-09 | — | — | WO | disclosed |
| WO-1998054190-A1 | NOVEL COMPOUNDS | ASTRA PHARMACEUTICALS LTD. (GB) | 1998-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014634-A1 | Thieno[2,3-d]pyrimidinediones and their use as pharmaceuticals | DPYD, TYMP, TYMS | ERCC1 994/4885ERCC5 790/4885FEN1 602/4885 |
| US-20020183337-A1 | For use in immunosuppression; for reducing the risk of, a reversible obstructive airways disease | TPMT, TSLP, TYMP | ERCC1 585/4885ERCC5 288/4885FEN1 166/4885 |
| US-20030191142-A1 | Thieno[2,3-d]pyrimidinediones, their preparation and use in therapy | TYMP, DPYD, TYMS | ERCC1 557/4885ERCC5 279/4885FEN1 290/4885 |
| US-20040122028-A1 | Novel compounds | DPYD, TYMS, TYMP | ERCC1 287/4885ERCC5 234/4885FEN1 242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.